EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study

Yusuf A Rajabally iD, Joumana Freiha, Young Gi Min iD, Chinar Osman iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70429 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Yusuf A Rajabally und 3 weiteren Autor:innen. Beteiligte Einrichtung: Aston Medical School, Aston University, Birmingham, UK. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunologic Factors, Immunoglobulins, Intravenous, Immunoglobulins. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunoglobulin dosing is individualised in chronic inflammatory demyelinating polyneuropathy (CIDP).

Methods

We retrospectively compared differences in presentation/outcomes/side effects in subjects on very high dose immunoglobulin defined as ≥ 2 g/kg every 3 weeks (‘Group A’) and subjects on ≤ 1 g/kg every 3 weeks (‘Group B’), from 2 UK centres.

Results

One‐hundred and eight subjects with CIDP received immunoglobulins. Group A consisted of 12 subjects (11.1%). Mean dose was 2.63 g/kg every 3 weeks (SD: 0.71). Six subjects (50%) had typical CIDP, 3 (25%) had motor CIDP, and 3 (25%) had multifocal CIDP. Group B consisted of 40 subjects (37%) on a mean dose of 0.47 g/kg every 3 weeks (SD: 0.16). Compared to subjects from Group B, subjects from Group A had greater pre‐treatment disability ( p = 0.029), more common associated autoimmune disease ( p = 0.034), worse post‐treatment outcome ( p = 0.005) and a longer time to maximal improvement ( p = 0.041). No differences were found between the two groups for age/gender/weight/acuteness of presentation/side‐effects. Occurrence of any side‐effect ( p = 0.005), and of thromboembolic complication ( p = 0.022), were associated with presence of another autoimmune disease.

Conclusions

Very high dose immunoglobulin may be partially effective in a minority of subjects with CIDP. Subjects treated with very high dose immunoglobulin may have greater pre‐treatment disability, be more likely to have another autoimmune disease, have worse post‐treatment outcomes, and take longer to reach maximal improvement, than subjects on lower doses. Concurrent autoimmune disease may increase immunoglobulin‐induced thromboembolic risk. Earlier consideration of alternative therapies may be more appropriate than immunoglobulin dose escalation in subjects with suboptimal immunoglobulin response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunologic FactorsImmunoglobulins, IntravenousImmunoglobulinsHumansMaleFemaleUnited KingdomMiddle AgedRetrospective StudiesAgedTreatment OutcomeAdultAged, 80 and over

Stichwörter der Autor:innen

chronic inflammatory demyelinating polyneuropathyimmunoglobulinoutcomeseverityvery high dose

Substanzen

Immunologic FactorsImmunoglobulins, IntravenousImmunoglobulins

Autor:innen und Institutionen

  • Aston Medical School, Aston University, Birmingham, UK.
  • Inflammatory Neuropathy Service, Department of Neurology, University Hospitals Birmingham, Birmingham, UK.
  • Wessex Neurological Centre, University Hospital Southampton, Southampton, UK.
  • Department of Neurology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Yusuf A Rajabally, Young Gi Min, Chinar Osman

Zitieren

APA

Rajabally, Y. A., Freiha, J., Min, Y. G., & Osman, C. (2025). Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study. European Journal of Neurology. https://doi.org/10.1111/ene.70429

Vancouver

Rajabally YA, Freiha J, Min YG, Osman C. Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study. European Journal of Neurology. 2025. doi:10.1111/ene.70429

BibTeX
@article{Rajabally2025,
  author = {Rajabally, Yusuf A and Freiha, Joumana and Min, Young Gi and Osman, Chinar},
  title = {Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70429}
}
Kostenlos starten →